Combination Studies With Campto For CRC
Several Phase I/II studies of Rhone-Poulenc Rorer's Campto (irinotecan)in combination with 5-fluorouracil and folinic acid in patients with colorectal cancer were presented at ASCO. The drug is already registered for second-line, single-agent treatment of the disease in Europe, the USA and Japan.
A total of eight Phase I/II studies, using a variety of administration regimens, are complete or ongoing. Data from these studies, presented at the ASCO meeting, revealed preliminary response rates in excess of 30% with the combination.
"The preliminary results of the various combination studies confirm Campto's tolerability in association with 5-FU and folinic acid, [and] antitumor activity has been observed at nontoxic doses," said a spokesman for the company. The task now is to select the best combination regimen to advance into study for first-line treatment of CRC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze